Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice

CONCLUSIONS: The NK1 regimen improved vomiting control at cycle 1 and, when introduced at cycle 2, significantly improved both nausea and vomiting. The biased NK1 selection for higher-risk patients may have dampened the differences between groups at cycle 1. These findings support enhanced control of T-DXd-related nausea and vomiting with NK1RA.PMID:38529378 | PMC:PMC10961432 | DOI:10.3389/fonc.2024.1374547

Source: Cancer Control - March 26, 2024 Category: Cancer & Oncology Authors: Giulia Notini Matteo Maria Naldini Lorenzo Sica Giulia Viale Alessia Rognone Stefania Zambelli Patrizia Zucchinelli Marta Piras Carlo Bosi Marco Mariani Daniela Aldrighetti Giampaolo Bianchini Luca Licata Source Type: research